Castle Biosciences CEO Derek J. Maetzold reports sale of $523,329.668 in common shares

CSTL•2026-11-04

Castle Biosciences CEO Derek J. Maetzold sold 14,496 common shares on Nov. 2, 2026, in transactions totaling $523,329.668.

1. Share sale

Maetzold sold 12,764 shares at $36.005 each and 1,732 shares at $36.814 each. After the transactions, he held 3,904 shares directly and 152,038 shares indirectly through trusts.

Sources

Castle Biosciences CEO Derek J. Maetzold reports sale of $523,329.668 in common shares

Sec

Castle Biosciences CEO Derek J. Maetzold reports sale of $523,329.668 in common shares

1. Share sale

Related News

Microsoft director Emma Walmsley does not seek re-election

Pursuit Q3 2026 adjusted EBITDA rises 7% year over year to USD 125 million

Adaptive Biotechnologies Q3 revenue falls 11% but beats estimates

Sources

Castle Biosciences CEO Derek J. Maetzold reports sale of $523,329.668 in common shares

Cambridge Associates says US midterm results do not warrant portfolio changes

First Internet Bancorp to attend KBW Fintech Ecosystem Conference